Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Initial Clinical Activity and Safety of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma

Adam D. Cohen, MD, Simon J Harrison, MBBS MRCP (UK) PhDFRCPath (UK) FRACP, Amrita Krishnan, MD, Rafael Fonseca, MD, Peter A Forsberg, MD, Andrew Spencer, Jesus G. Berdeja, MD, Jacob P. Laubach, MD, Mengsong Li, Voleak Choeurng, Anjali Vaze, Divya Samineni, Teiko Sumiyoshi, James Cooper, Bernard M Fine, Suzanne Trudel

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-136985

Published: 2020

Journal Articles

Novel Alkylating Agent Melflufen Displays Potent Efficacy in Plasma Cell Leukemia Samples and Other High-Risk Subtypes of Multiple Myeloma

Beau M Idler, Olivia Perez De Acha, MD, Owen Lockerbie, PhD, Ken Flanagan, PhD, Fredrik Lehmann, MSc, PhD, Peter A Forsberg, MD, Tomer M Mark, MD MS, Daniel W. Sherbenou, MD PhD

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-138762

Published: 2020

Journal Articles

Myeloma Drug Sensitivity Testing to Optimize Retreatment with Anti-CD38 Monoclonal Antibodies in Daratumumab-Refractory Patients

Olivia Perez De Acha, MD, Beau M Idler, Zachary J Walker, BS, MS, Peter A Forsberg, MD, Tomer M Mark, MD MS, Daniel W. Sherbenou, MD PhD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-137819

Published: 2020

Journal Articles

Broad Efficacy of the Translation Inhibitor Omacetaxine in Relapsed/Refractory Multiple Myeloma Samples

Zachary J Walker, BS, MS, Beau M Idler, BA, Michael J VanWyngarden, BS, Brett M. Stevens, PhD, Shelby C Bearrows, BS, Lorraine N Davis, BS, Andrew Hammes, MS, Clayton Smith, MD, Craig T Jordan, PhD, Tomer M Mark, MD MS, Peter A Forsberg, MD, Daniel W Sherbenou, MD PhD

Blood (2019) 134 (Supplement_1): 4404.

https://doi.org/10.1182/blood-2019-121937

Published: 2019

Journal Articles

Chronic Graft Versus Host Disease Burden and Relapse Rates Are Lower with Comparable Overall Survival and Graft Versus Host Disease Free, Relapse Free Survival Following Adult Umbilical Cord Blood Compared to Matched Sibling Peripheral Blood Stem Cell Transplantation

Prashant Sharma, MD, Enkhtsetseg Purev, MD PhD, Bradley M. Haverkos, MD MPH, MS, Daniel A Pollyea, MD, Clayton Smith, MD, Manali Kamdar, Daniel W Sherbenou, MD PhD, Tomer M Mark, MD MS, Peter A Forsberg, MD, Jonathan A Gutman, MD

Blood (2018) 132 (Supplement 1): 4660.

https://doi.org/10.1182/blood-2018-99-119690

Published: 2018

Journal Articles

A Rapid Functional Screen for Small Molecule and Monoclonal Antibody Drug Sensitivity in Multiple Myeloma Patients

Zachary J Walker, MS, Michael J VanWyngarden, BS, Brett M Stevens, PhD, Christophe Langouët-Astrie, MS, Clayton Smith, MD, Brent E Palmer, PhD, Peter A Forsberg, MD, Tomer M Mark, MD MS, Craig T Jordan, PhD, Daniel W Sherbenou, MD PhD

Blood (2018) 132 (Supplement 1): 3203.

https://doi.org/10.1182/blood-2018-99-111394

Published: 2018

Journal Articles

Cellular Proliferation By Multiplex Immunohistochemistry Identifies Aggressive Disease Behavior in Relapsed Multiple Myeloma

Peter A. Forsberg, MD, Tomer M Mark, MDMSc, Daniel W. Sherbenou, MDPhD, Andrew Hammes, MS, Adriana C. Rossi, MDMSc, Ruben Niesvizky, MD, David S Jayabalan, MSc, Scott Ely, MDMPH

Blood (2017) 130 (Supplement 1): 3059.

https://doi.org/10.1182/blood.V130.Suppl_1.3059.3059

Published: 2017

Journal Articles

Carfilzomib Induction with Lenalidomide and Clarithromycin Consolidation and Lenalidomide Maintenance (CarBiRD) for Multiple Myeloma (MM)

Peter A. Forsberg, MD, Adriana C Rossi, MD, MSc, Roger N Pearse, MD PhD, Arthur Perry, PA, Karen Pekle, NP, David Jayabalan, BSMS, MSc, Scott Ely, MD MPH, Morton Coleman, MD, John N. Allan, MD, Ruben Niesvizky, MD, Tomer Mark, MD MSc

Blood (2016) 128 (22): 4518.

https://doi.org/10.1182/blood.V128.22.4518.4518

Published: 2016

Journal Articles

Rising Plasma Cell Proliferation By Ki67/CD138 Ratio at Relapse Is a Marker of High Risk Disease in Multiple Myeloma

Peter A. Forsberg, MD, Tomer M Mark, MD MSc, Sujitha Yadlapati, MBBS, Adriana C Rossi, MD MHS, Roger N Pearse, MD PhD, Karen Pekle, NP, Arthur Perry, PA, Morton Coleman, MD, David Jayabalan, BSMS, MSc, Ruben Niesvizky, MD, Scott Ely, MD MPH

Blood (2015) 126 (23): 2991.

https://doi.org/10.1182/blood.V126.23.2991.2991

Published: 2015

NARROW

Initial Clinical Activity and Safety of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma

Novel Alkylating Agent Melflufen Displays Potent Efficacy in Plasma Cell Leukemia Samples and Other High-Risk Subtypes of Multiple Myeloma

Myeloma Drug Sensitivity Testing to Optimize Retreatment with Anti-CD38 Monoclonal Antibodies in Daratumumab-Refractory Patients

Broad Efficacy of the Translation Inhibitor Omacetaxine in Relapsed/Refractory Multiple Myeloma Samples

Chronic Graft Versus Host Disease Burden and Relapse Rates Are Lower with Comparable Overall Survival and Graft Versus Host Disease Free, Relapse Free Survival Following Adult Umbilical Cord Blood Compared to Matched Sibling Peripheral Blood Stem Cell Transplantation

A Rapid Functional Screen for Small Molecule and Monoclonal Antibody Drug Sensitivity in Multiple Myeloma Patients

Cellular Proliferation By Multiplex Immunohistochemistry Identifies Aggressive Disease Behavior in Relapsed Multiple Myeloma

Carfilzomib Induction with Lenalidomide and Clarithromycin Consolidation and Lenalidomide Maintenance (CarBiRD) for Multiple Myeloma (MM)

Rising Plasma Cell Proliferation By Ki67/CD138 Ratio at Relapse Is a Marker of High Risk Disease in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only